Gary McCord is currently Vice President of Sales and Market at TriReme Medical, a California-based subsidiary of QT Vascular, which develops and manufacturers therapies for complex vascular disease.

Prior to this, he was Vice President of Business Development (2011-14) at Sapheon, a developer of closure systems for treatment of venous reflux disease, now part of Medtronic. From 2009-12 he was Director of Coronary Franchise at Cardiovascular Systems, Inc., where he was also a territorial and regional sales manager (2004-09).

Prior to joining CSI, Mr. McCord held various sales and management positions with Fox Hollow Technologies, Pilot Cardiovascular Systems, Heart Technologies, Ventritex, Interventional Technologies, and X-Technologies—all privately held entrepreneurial cardiology enterprises later acquired by companies such as C.R. Bard, Boston Scientific, Guidant, and St. Jude Medical.